MC1568

MC1568 is a **selective inhibitor of class IIa histone deacetylases (HDACs)**, specifically targeting HDAC4, HDAC5, HDAC7, and HDAC9 and associated with moderate activity also against class IIb HDACs (HDAC6, HDAC10), with no significant inhibition of class I HDACs (HDAC1, HDAC2, HDAC3)[1][5]. By selectively inhibiting these HDACs, MC1568 modulates tissue-specific epigenetic regulation and has demonstrated therapeutic potential through mechanisms such as **arresting myogenesis by modifying MEF2D activity and complex formation**, as well as interfering with RAR and PPARγ signaling pathways[1]. In preclinical studies, MC1568 has shown **neuroprotective activity** by reducing α-synuclein accumulation in Parkinson's disease models without marked cytotoxicity[2], **enhanced insulin secretion and protection of β-cells** in type 2 diabetes models[3], and **amelioration of podocyte injury and proteinuria in nephrotic syndrome and kidney injury models**[5]. MC1568 is presently a research tool compound and not approved for clinical use.

Other names

(E)-3-[4-[(E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-N-hydroxyprop-2-enamide